Cardiovascular disease biotech company Scribe (SCTX.US) sets IPO price at $13-15 per share, aiming to raise $100 millions

Zhitong Finance APP has learned that Scribe Therapeutics, a biotechnology company dedicated to developing CRISPR gene therapies for high cholesterol and currently in Phase I clinical trials, announced its initial public offering (IPO) terms on Monday. The company plans to issue 7.2 million shares at a price range of $13 to $15 per share, raising $100 million. The company intends to list on the Nasdaq under the stock code "SCTX."